Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer
View/ Open
Volume
13
Publisher
DOI
10.3390/cancers13081926
Journal
CANCERS
Issue
Metadata
Show full item recordAbstract
CAR T cells have revolutionised the treatment of haematological malignancies. Despite
this, several obstacles still prohibit their widespread use and efficacy. One of these barriers is the use
of autologous T cells as the carrier of the CAR. The individual production of CAR T cells results in
large variation in the product, greater wait times for treatment and higher costs. To overcome this
several novel approaches have emerged that utilise allogeneic cells, so called “off the shelf” CAR T
cells. In this Review, we describe the different approaches that have been used to produce allogeneic
CAR T to date, as well as their current pre-clinical and clinical progress.